Covid-19 vaccines pricing policy options for low-income and middle- income countries
Bibliographic Data
| ID | 21879570 |
|---|---|
| Authors | JAVIER GUZMÁN (0000-0002-8194-039X, Management Sciences for Health, corresponding author), Tamara Hafner (0000-0002-4710-0979, Management Sciences for Health), Lalla Arkia Maiga (0000-0002-5733-8745, Management Sciences for Health), Ursula Giedion (Inter-American Development Bank) |
| Year | 2021 |
| Volume | 6 |
| Issue | 3 |
| Pages | e005347 |
| Publication date | 2021-03-01 |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | BMJ Global Health (JOURNAL) |
| Journal identifiers | ISSN: 2059-7908 • E-ISSN: 2059-7908 |
| Publisher | BMJ (PUBLISHER • GB) |
| DOI | 10.1136/bmjgh-2021-005347 |
| PMID | 33727281 |
| OpenAlex | W3137561087 |
| Language | EN |
| Citations received | 5 |
| References cited | 3 |
box Affordable and equitable access to medical products and technologies have long been a challenge for health systems.1 The COVID-19 pandemic has further highlighted this critical challenge, making it a priority agenda issue for countries globally. Prices drive health expenditure and ultimately population-wide coverage and access to novel products. For example, DIME, an Inter-American Development Bank-funded project, estimated that Costa Rica, Ecuador and Mexico would have to allocate five times their annual immunisation budgets to cover their high-risk populations if prices recently announced for two leading vaccine candidates in high-income countries were held for these three countries.1 The high prices increase the financial burden for populations and governments.2 As part of a broader policymaking process, one role for government is developing and implementing well-planned pricing policies and guidelines to help ensure affordable and equitable access.3 The COVID-19 pandemic, however, limits pricing policy options. It is therefore necessary to consider what
Business · Developing country · Development economics · Economic growth · Economics · Environmental health · Health care · Pandemic · Population · Public economics · Global Maternal and Child Health · Healthcare Systems and Reforms · Medicine · Pharmaceutical Economics and Policy · Health Policy
Mieux qu’un compromis, une troisième voie
How can new TB vaccines be effectively introduced in Indonesia? Insights from diverse stakeholders
Barriers to Covid-19 Health Products in Low-and Middle-Income Countries During the Covid-19 Pandemic
Covid-19 vaccine preferences for pregnant and lactating women in Bangladesh and Kenya
Overcoming non-patient and health professional’s barriers to Covid-19 vaccination in pregnancy
| Citations per year | 1.25 |
|---|---|
| Citation span | 2022 - 2026 (5) |
| Highly cited | No |